In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Working Disclosures: Indian PIL Flags Breaches

This article was originally published in Scrip

Executive Summary

A public interest litigation (PIL) has brought back to focus a seemingly contentious issue around mandatory disclosures pertaining to the working of patents in India.

You may also be interested in...



Leaked UK-India Draft FTA Text: Eyes On Provision That Felled Glivec Patent

A leaked draft intellectual property chapter, purported to be the UK’s opening proposal, from a planned bilateral free trade agreement with India features several controversial provisions. These include nullifying an Indian regulation that disallows patents for "incremental" inventions, requirements around mandatory disclosures on the working of patents, as well as the introduction of data exclusivity. Legal experts weigh in on some of these long-standing contentious issues.

Leaked UK-India Draft FTA Text: Eyes On Provision That Felled Glivec Patent

A leaked draft intellectual property chapter, purported to be the UK’s opening proposal, from a planned bilateral free trade agreement with India features several controversial provisions. These include nullifying an Indian regulation that disallows patents for "incremental" inventions, requirements around mandatory disclosures on the working of patents, as well as the introduction of data exclusivity. Legal experts weigh in on some of these long-standing contentious issues.

Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India

Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel